United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Hoth Therapeutics (NASDAQ: HOTH) stakes claim on emerging oncodermatology space with dual patent filings for HT-001 Hoth Therapeutics files dual patents for HT-001 in oncology dermatology. Find out what this means for its IP strategy and cancer care positioning. bySrinathJanuary 5, 2026